Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Snapdragon Chemistry, uma empresa da Cambrex, é reconhecida com o CPhI Pharma Award por desenvolvimento de API
  • USA - Deutsch
  • USA - English
  • USA - English
  • USA - Français
  • Latin America - español
  • USA - español

Cambrex Logo

News provided by

Cambrex

Oct 25, 2023, 04:57 ET

Share this article

Share toX

Share this article

Share toX

 EAST RUTHERFORD, Nova Jersey, 25 de outubro de 2023 /PRNewswire/ -- A Cambrex, uma organização líder global em desenvolvimento e fabricação por contrato (CDMO), anunciou hoje que a Snapdragon Chemistry foi selecionada como vencedora do API Development Award, apresentado no CPhI Pharma Awards em Barcelona, Espanha. O prêmio anual é concedido a uma empresa que demonstre inovação em tecnologias, produtos, processos e serviços para o desenvolvimento e fabricação de ingredientes farmacêuticos ativos (APIs).

Continue Reading
Snapdragon Chemistry, a Cambrex Company, Recognized with CPhI Pharma Award for API Development
Snapdragon Chemistry, a Cambrex Company, Recognized with CPhI Pharma Award for API Development
Snapdragon Logo
Snapdragon Logo

"A colaboração Snapdragon-Amgen neste projeto ultrapassou os limites da tecnologia para projetar um processo de fluxo seguro, permitindo o processo contínuo para esta importante molécula", disse o Dr. Matt Bio, diretor científico da Cambrex. "A Snapdragon tem a honra de receber este prêmio, e estamos orgulhosos da capacidade da nossa equipe em inovar e entregar ao nosso cliente".

A inscrição da Snapdragon, que foi analisada por um painel global de especialistas independentes do setor, documentou o desenvolvimento de um processo de fabricação de fluxo contínuo de temperatura ultra-alta para racemização do subproduto sotorsib (LUMAKRASTM) P-dione do processo de fabricação comercial da Amgen. Essa tecnologia resultou em uma redução de 58% na intensidade de massa do processo e estima-se que economize milhares de toneladas métricas de resíduos.

"Este trabalho destaca o valor da química de fluxo para alcançar condições de processamento não possíveis nos reatores tradicionais de lotes", disse o Dr. Matthew Beaver, Diretor de Desenvolvimento de Processos da Amgen. "Por meio dessa colaboração com a Snapdragon, a Amgen foi capaz de desenvolver um processo de racemização térmica seguro e expansível que maximiza o rendimento e minimiza nossa pegada ambiental".

A Snapdragon, que foi adquirida pela Cambrex no início de 2023, concluiu recentemente uma expansão de 12.000 metros quadrados em sua instalação em Waltham, Massachusetts, reforçando sua capacidade de desenvolvimento de processos com novas suítes de pesquisa e desenvolvimento de processos, um pacote de estabilidade de GMP e um quinto laboratório em larga escala de GMP.

Sobre a Snapdragon Chemistry
é uma empresa da Cambrex especializada em ingredientes farmacêuticos ativos (API) em lotes e desenvolvimento de processos de fluxo contínuo, utilizando tecnologia de automação de última geração e equipamentos proprietários para resolver desafios complexos de processo e desenvolvimento analítico. Com P&D e manufatura com sede em Waltham, Massachusetts, os mais de 70 funcionários da Snapdragon vêm com fortes laços com a comunidade científica local, tendo 31 cientistas com doutorado na equipe. Para mais informações, acesse [email protected].

Sobre a Cambrex:a
Cambrex é uma organização líder global em desenvolvimento e fabricação mediante contrato (CDMO) que oferece serviços de substâncias farmacêuticas, produtos farmacêuticos e análises em todo o ciclo de vida de medicamentos. Com mais de 40 anos de experiência e uma equipe crescente de mais de 2.400 especialistas atendendo clientes globais da América do Norte e Europa, a Cambrex é uma parceira confiável para o desenvolvimento e fabricação de formas de dosagem acabadas em mercados de marca e genéricos.

A Cambrex oferece uma gama de tecnologias e recursos especializados de fármacos, incluindo biocatálise, fluxo contínuo, substâncias controladas, ciência de estado sólido, caracterização de materiais, armazenamento de estabilidade e APIs altamente potentes. Além disso, a Cambrex pode fornecer formas de dosagem convencionais, incluindo sólidos, semissólidos e líquidos orais, e tem experiência na fabricação de formas de administração especiais como comprimidos de liberação modificada, combinação de dose fixa, pediátrica, comprimidos de duas camadas, stick packs, produtos tópicos, substâncias controladas, pomadas estéreis e não estéreis.

Foto: https://mma.prnewswire.com/media/2256573/Cambrex_Snapdargon.jpg
Logotipo: https://mma.prnewswire.com/media/2236065/4360596/Cambrex_logo.jpg
Logotipo:https://mma.prnewswire.com/media/2076582/4360601/Snapdragon_Logo.jpg

FONTE Cambrex

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Cambrex expandirá la fabricación de API y fortalecerá el suministro de medicamentos en EE. UU.

Cambrex expandirá la fabricación de API y fortalecerá el suministro de medicamentos en EE. UU.

Cambrex, una organización líder mundial en desarrollo y fabricación por contrato (CDMO), anunció hoy una inversión de 120 millones de dólares para...

Cambrex dévoile un investissement de 120 millions de dollars pour développer la fabrication d'IPA et renforcer la résilience de l'approvisionnement en médicaments aux États-Unis

Cambrex dévoile un investissement de 120 millions de dollars pour développer la fabrication d'IPA et renforcer la résilience de l'approvisionnement en médicaments aux États-Unis

Cambrex, une organisation mondiale de développement et de fabrication sous contrat (CDMO) de premier plan, a annoncé aujourd'hui un investissement de ...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Pharmaceuticals

Pharmaceuticals

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.